Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 18, 2022 - Issue 6
Submit an article Journal homepage
1,641
Views
0
CrossRef citations to date
0
Altmetric
Public Health – Review

A guideline for economic evaluations of vaccines and immunization programs in China

Hai Fanga China Center for Health Development Studies, Peking University, Beijing, China;n Institute for Global Health and Development, Peking University, Beijing, ChinaCorrespondence[email protected]
View further author information
,
Chen Chenb School of Public Health, Wuhan University, Wuhan, Hubei Province, ChinaView further author information
,
Yu Fangc Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi’an Jiaotong University, Xi’an, Shaanxi Province, ChinaView further author information
,
Xiaoning Hed School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, ChinaView further author information
,
Zhiyuan Houe School of Public Health, Fudan University, Shanghai, ChinaView further author information
,
Minghuan Jiangc Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi’an Jiaotong University, Xi’an, Shaanxi Province, ChinaView further author information
,
Yawen Jiangf School of Public Health (Shenzhen), Sun Yat-Sen University, Shenzhen, Guangdong Province, ChinaView further author information
,
Shunping Lig School of Public Health, Shandong University, Jinan, Shandong Province, ChinaView further author information
,
Yang Liuh Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and Tropical Medicine, London, UK;i Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UKView further author information
,
Binyan Suij School of Social Development and Public Policy, Beijing Normal University, Beijing, ChinaView further author information
,
Qiang Sung School of Public Health, Shandong University, Jinan, Shandong Province, ChinaView further author information
,
Jing Wud School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, ChinaView further author information
,
Tingting Xuk School of Public Health, Capital Medical University, Beijing, ChinaView further author information
,
Juan Yange School of Public Health, Fudan University, Shanghai, ChinaView further author information
,
Zundong Yinl National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, ChinaView further author information
,
Xiaohua Yinge School of Public Health, Fudan University, Shanghai, ChinaView further author information
,
Beibei Yuana China Center for Health Development Studies, Peking University, Beijing, ChinaView further author information
,
Hui Zhengl National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, ChinaView further author information
&
Yaming Zhengm Division of Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing, ChinaView further author information
 show all
Article: 2132802 | Received 24 Aug 2022, Accepted 02 Oct 2022, Published online: 26 Oct 2022

References

  • Chinese Center for Disease Control and Prevention. Achievements of 40 years’ national immunization programs in China. 2018.
  • Yu W, Lee LA, Liu Y, Scherpbier RW, Wen N, Zhang G, Zhu X, Ning G, Wang F, Li Y, et al. Vaccine-preventable disease control in the People’s Republic of China: 1949-2016. Vaccine. 2018 Dec 18;36(52):1–9. doi:10.1016/j.vaccine.2018.10.005. Epub 2018 Nov 26. PMID: 30497834; PMCID: PMC7115483.
  • Chinese Center for Disease Control and Prevention, Childhood Immunization Schedule for National Immunization Program Vaccines. Version 2021. [ accessed 2022 July 23]. https://www.chinacdc.cn/nip/kyjz/mycxbjsm/mycxb/
  • Lai X, Fang H. Immunization programs in the USA, the UK, Germany, and Japan, and their implication for vaccine financing. Natl Med J China. 2020;100:85–88.
  • World Health Organization. Principles and considerations for adding a vaccine to a national immunization program: from decision to implementation and monitoring. Geneva. 2014.
  • World Health Organization. Guidance on the economic evaluation of influenza vaccination. Geneva. 2016.
  • World Health Organization. WHO guide for standardization of economic evaluations of immunization programs. 2nd ed. Geneva: World Health Organization. 2019 Oct.
  • Mauskopf J, Standaert B, Connolly MP, Culyer AJ, Garrison LP, Hutubessy R, Jit M, Pitman R, Revill P, Severens JL. Economic analysis of vaccination programs: an ISPOR good practices for outcomes research task force report. Value Health. 2018;21(10):1133–49. doi:10.1016/j.jval.2018.08.005.
  • Ultsch B, Damm O, Beutels P, Bilcke J, Brüggenjürgen B, Gerber-Grote A, Greiner W, Hanquet G, Hutubessy R, Jit M, et al. Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community. Pharmacoeconomics. 2016 Mar;34(3):227–44. doi:10.1007/s40273-015-0335-2. PMID: 26477039; PMCID: PMC4766233.
  • United States Advisory Committee on Immunization Practices. Guidance for health economics studies presented to the Advisory Committee on Immunization Practices, 2019 update.
  • Wang G, Shao M. The development of China’s vaccine industry in the past decade: the perspective from drug regulatory science. Hum Vaccin Immunother. 2021 Dec 2;17(12):5666–72. doi:10.1080/21645515.2021.2002640. Epub 2021 Dec 2. PMID: 34856877; PMCID: PMC8903904.
  • WHO and UNICEF 2020. WHO and UNICEF estimates of national immunization coverage in China. 2021 July 15.
  • Zheng Y, Rodewald L, Yang J, Qin Y, Pang M, Feng L, Yu H. The landscape of vaccines in China: history, classification, supply, and price. BMC Infect Dis. 2018;18(1):502. doi:10.1186/s12879-018-3422-0.
  • Pan XF, Griffiths UK, Pennington M, Yu H, Jit M. Systematic review of economic evaluations of vaccination programs in mainland China: are they sufficient to inform decision making? Vaccine. 2015 Nov 17;33(46):6164–72. doi:10.1016/j.vaccine.2015.09.081. Epub 2015 Oct 2. PMID: 26435189.
  • National People’s Congress of the People’s Republic of China. Vaccine Administration Law. [ accessed 2022 July 26]. http://www.npc.gov.cn/englishnpc/c23934/202012/0b1fd779c29e49bd99eb0e65b66aa783.shtml
  • Wang W, Wang Y, Wang Y, Yan F, Wang N, Fu C. Vaccine bidding, procurement and distribution management practices in mainland China: a nationwide study. Vaccine. 2021 Dec 20;39(52):7584–89. doi:10.1016/j.vaccine.2021.11.020. Epub 2021 Nov 19. PMID: 34802784.
  • Lv M, Fang R, Wu J, Pang X, Deng Y, Lei T, Xie Z. The free vaccination policy of influenza in Beijing, China: the vaccine coverage and its associated factors. Vaccine. 2016 Apr 19;34(18):2135–40. doi:10.1016/j.vaccine.2016.02.032. Epub 2016 Feb 23. PMID: 26917011.
  • Zhang M, Chen H, Wu F, Li Q, Lin Q, Cao H, Zhou X, Gu Z, Chen Q. Heightened willingness toward pneumococcal vaccination in the elderly population in Shenzhen, China: a cross-sectional study during the COVID-19 pandemic. Vaccines (Basel). 2021 Mar 3;9(3):212. doi:10.3390/vaccines9030212. PMID: 33802327; PMCID: PMC8000999.
  • Ministry of finance of the People’s Republic of China, information about fiscal subsides to Covid 19 vaccines and administrative vaccination fee. [ accessed 2022 July 26]. http://sbs.mof.gov.cn/gongzuodongtai/202109/t20210914_3752856.htm
  • Lai X, Peng Z, Qin Y, Feng L, Li Z, Feng Z, Fang H. Financing strategies and cost estimates of influenza vaccination for the elderly in China: explore a multi-party co-payment mechanism. Natl Med J China. 2021;101(26):2029–36. doi:10.3760/cma.j.cn112137-20210205-00365.
  • GBD 2020. Release 1, vaccine coverage collaborators. Measuring routine childhood vaccination coverage in 204 countries and territories, 1980-2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1. Lancet. 2021 Aug 7;398(10299):503–21. doi:10.1016/S0140-6736(21)00984-3. Epub 2021 Jul 21. PMID: 34273291; PMCID: PMC8358924.
  • Zhang H, Garcia C, Yu W, Knoll MD, Lai X, Xu T, Jing R, Qin Y, Yin Z, Wahl B, et al. National and provincial impact and cost-effectiveness of Haemophilus influenzae type b conjugate vaccine in China: a modeling analysis. BMC Med. 2021 Aug 11;19(1):181. doi:10.1186/s12916-021-02049-7. PMID: 34376214; PMCID: PMC8356460.
  • Lai X, Wahl B, Yu W, Xu T, Zhang H, Garcia C, Qin Y, Guo Y, Yin Z, Knoll MD, et al. National, regional, and provincial disease burden attributed to Streptococcus pneumoniae and Haemophilus influenzae type b in children in China: modelled estimates for 2010-17. Lancet Reg Health West Pac. 2022 Mar 16;22:100430. doi:10.1016/j.lanwpc.2022.100430. PMID: 35308577; PMCID: PMC8928075.
  • Wang J, Zhang H, Zhang H, Fang H. Public health impact and cost-effectiveness of rotavirus vaccination in China: comparison between private market provision and national immunization programs. Hum Vaccin Immunother. 2022 Jul 11;2090162. doi:10.1080/21645515.2022.2090162. Epub ahead of print. PMID: 35816415.
  • Hou Z, Chang J, Yue D, Fang H, Meng Q, Zhang Y. Determinants of willingness to pay for self-paid vaccines in China. Vaccine. 2014 Jul 31;32(35):4471–77. doi:10.1016/j.vaccine.2014.06.047. Epub 2014 Jun 23. PMID: 24968160.
  • Song XB, Zhao QJ, Zhou Z, Fang Y. Health economic evaluation of bivalent human papilloma virus vaccine in China: based on the dynamic model. Zhonghua Yu Fang Yi Xue Za Zhi . 2017 Sep 6;51(9):814–20. doi:10.3760/cma.j.issn.0253-9624.2017.09.008. Chinese PMID: 28881547.
  • Yu W, Lu M, Wang H, Rodewald L, Ji S, Ma C, Li Y, Zheng J, Song Y, Wang M, et al. Routine immunization services costs and financing in China, 2015. Vaccine. 2018 May 17;36(21):3041–47. doi:10.1016/j.vaccine.2018.04.008. Epub 2018 Apr 20. PMID: 29685593.
  • Liu GG. China guidelines for pharmacoeconomic evaluations. Chinese-English version. Beijing China: China Market Press; 2020.
  • China National Bureau of Statistics. China statistic yearbook 2021. Beijing: China Statistic Press; 2022 July.
  • Jackson CH, Thompson SG, Sharples LD Accounting for uncertainty in health economic decision models by using model averaging. J R Stat Soc Ser A Stat Soc. 2009 Apr;172(2):383–404. doi:10.1111/j.1467-985X.2008.00573.x. PMID: 19381329; PMCID: PMC2667305.
  • Hu Y, Chen Y. Evaluating childhood vaccination coverage of NIP vaccines: coverage survey versus Zhejiang Provincial Immunization Information System. Int J Environ Res Public Health. 2017 Jul 11;14(7):758. doi:10.3390/ijerph14070758. PMID: 28696387; PMCID: PMC5551196.
  • Ye L, Chen J, Fang T, Ma R, Wang J, Pan X, Dong H, Xu G. Vaccination coverage estimates and utilization patterns of inactivated enterovirus 71 vaccine post vaccine introduction in Ningbo, China. BMC Public Health. 2021;21(1):1118. doi:10.1186/s12889-021-11198-6.
  • Lin SY, Zhang SY, Chantler T, Sun FY, Zou JT, Cheng JJ, Chen YQ, Sun M, Howard N. Vaccination coverage determinants in low uptake areas of China: a qualitative study of provider perspectives in Sichuan, Guangdong, and Henan Provinces. Hum Vaccin Immunother. 2022 Dec 31;18(1):2030623. doi:10.1080/21645515.2022.2030623. Epub 2022 Feb 17. PMID: 35176962; PMCID: PMC8993075.
  • Ward T, Mujica-Mota RE, Spencer AE, Medina-Lara A. Incorporating equity concerns in cost-effectiveness analyses: a systematic literature review. Pharmacoeconomics. 2022 Jan;40(1):45–64. doi:10.1007/s40273-021-01094-7. Epub 2021 Oct 29. PMID: 34713423.
  • Levin CE, Sharma M, Olson Z, Verguet S, Shi JF, Wang SM, Qiao YL, Jamison DT, Kim JJ. An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China. Vaccine. 2015 Jun 4;33(24):2830–41. doi:10.1016/j.vaccine.2015.02.052. Epub 2015 Mar 12. PMID: 25770785.
  • Fang H China guidelines for vaccine economic evaluation. Peking University Health Science Center-Chinese Center for Disease Control and Prevention Joint Center for Vaccine Economics. 2022 ed. In Chinese. https://www.cchds.pku.edu.cn/docs/2022-06/20220623221519493447.pdf
  • Luo Y, He H, Tang X, Wang S, Zhang J, Wu T, Chen Z. Cost-effectiveness of 2-dose human papillomavirus vaccination for 12-year-old girls in Zhejiang Province: implications for China’s expanded program on immunization. Hum Vaccin Immunother. 2020 Jul 2;16(7):1623–29. doi:10.1080/21645515.2019.1711299. Epub 2020 Mar 18. PMID: 32186953; PMCID: PMC7482859.
  • Ma X, Harripersaud K, Smith K, Fairley CK, Zou H, Zou Z, Wang Y, Zhuang G, Zhang L. Modeling the epidemiological impact and cost-effectiveness of a combined schoolgirl HPV vaccination and cervical cancer screening program among Chinese women. Hum Vaccin Immunother. 2021 Apr 3;17(4):1073–82. doi:10.1080/21645515.2020.1832835. Epub 2020 Dec 3. PMID: 33269990; PMCID: PMC8018426.
  • Mo X, Gai Tobe R, Wang L, Liu X, Wu B, Luo H, Nagata C, Mori R, Nakayama T. Cost-effectiveness analysis of different types of human papillomavirus vaccination combined with a cervical cancer screening program in mainland China. BMC Infect Dis. 2017 Jul 18;17(1):502. doi:10.1186/s12879-017-2592-5. PMID: 28720082; PMCID: PMC5516327.
  • Ning G, Yin Z, Li Y, Wang H, Yang W. Cost-effectiveness of the Haemophilus influenzae type b vaccine for infants in mainland China. Hum Vaccin Immunother. 2018 Jan 2;14(1):36–44. doi:10.1080/21645515.2017.1385687. Epub 2017 Nov 27. PMID: 29049002; PMCID: PMC5791576.
  • Shen K, Wasserman M, Liu D, Yang YH, Yang J, Guzauskas GF, Wang BCM, Hilton B, Farkouh R, Hozbor DF. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China. PLoS One. 2018 Jul 25;13(7):e0201245. doi:10.1371/journal.pone.0201245. PMID: 30044865; PMCID: PMC6059448.
  • Wang W, Song J, Wang J, Li Y, Deng H, Li M, Gao N, Zhai S, Dang S, Zhang X, et al. Cost-effectiveness of a national enterovirus 71 vaccination program in China. PLoS Negl Trop Dis. 2017 Sep 11;11(9):e0005899. doi:10.1371/journal.pntd.0005899. PMID: 28892475; PMCID: PMC5608421.
  • Wang XY, Riewpaiboon A, von Seidlein L, Chen XB, Kilgore PE, Ma JC, Qi SX, Zhang ZY, Hao ZY, Chen JC, et al. Potential cost-effectiveness of a rotavirus immunization program in rural China. Clin Infect Dis. 2009 Oct 15;49(8):1202–10. doi:10.1086/605632. PMID: 19739973.
  • Wu JT, Jit M, Zheng Y, Leung K, Xing W, Yang J, Liao Q, Cowling BJ, Yang B, Lau EH, et al. Routine pediatric enterovirus 71 vaccination in China: a cost-effectiveness analysis. PLoS Med. 2016 Mar 15;13(3):e1001975. doi:10.1371/journal.pmed.1001975. Erratum in: PLoS Med. 2016 Apr;13(4):e1002013. PMID: 26978565; PMCID: PMC4792415.
  • Zhao D, Gai Tobe R, Cui M, He J, Wu B. Cost-effectiveness of a 23-valent pneumococcal polysaccharide vaccine immunization programme for the elderly in Shanghai, China. Vaccine. 2016 Dec 7;34(50):6158–65. doi:10.1016/j.vaccine.2016.11.003. Epub 2016 Nov 9. PMID: 27838068.
  • Zhou H, He J, Wu B, Che D. Cost-effectiveness analysis of routine 13-valent pneumococcal conjugate vaccinations in Chinese infants. Hum Vaccin Immunother. 2018 Jun 3;14(6):1444–52. doi:10.1080/21645515.2018.1438794. Epub 2018 Apr 9. PMID: 29425054; PMCID: PMC6037447.
  • Zou Z, Fairley CK, Ong JJ, Hocking J, Canfell K, Ma X, Chow EPF, Xu X, Zhang L, Zhuang G Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis. Lancet Glob Health. 2020 Oct;8(10):e1335–44. doi:10.1016/S2214-109X(20)30277-1. PMID: 32971056.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.